Evidence map›Paper›PMID 38544901›Full record

ArticleTurkish journal of chemistry2024

Structure-activity relationship of anticancer drug candidate quinones.

Nadire Özenver, Neslihan Sönmez, Merve Yüzbaşioğlu Baran, Merve Yüzbaşioğlu Baran, Ayşe Uz, Lütfiye Ömür Demirezer

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nadire ÖzenverDepartment of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0001-9561-8994
Neslihan SönmezDepartment of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-1610-1338
Merve Yüzbaşioğlu BaranDepartment of Pharmacognosy, Gülhane Faculty of Pharmacy, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-7482-0429
Merve Yüzbaşioğlu BaranDepartment of Pharmacognosy, Gülhane Faculty of Pharmacy, University of Health Sciences, Ankara, Turkiye.ORCID https://orcid.org/0000-0003-3373-4759
Ayşe UzDepartment of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye.
Lütfiye Ömür DemirezerDepartment of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-5284-0744
Pharmac · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of the most prevalent cancer types worldwide. Chemotherapy is a substantial approach in the management of breast cancer despite the occurrence of chemotherapy-associated side effects and the development of multidrug resistance in cancer cells. At this point, a variety of quinone derivatives may represent potential as possible anticancer drug candidates due to possessing structural similarity towards clinically used anticancer drugs like doxorubicin. Therefore, we investigated the cytotoxic effects of various quinone derivatives with structural diversity towards a variety of breast cancer cells. We further determined their toxicity in healthy cells to evaluate their drug capability potential. Eighteen quinone derivatives (arbutin, hydroquinone, alkannin, lapachol, lawsone, juglone, aloe-emodin, aloin, cascaroside A (8-O-

Indexed as

alkannincancercytotoxicityjuglonenaphthoquinoneQuinone

Identifiers

PMID38544901
PMCPMC10965169
OpenAlexW4392364725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.